IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Tartour, Kevin ^a,b,c,d,e   Appourchaux, Romain ^a,b,c,d,e   Gaillard, Julien ^f   Nguyen, Xuan Nhi ^a,b,c,d,e   Durand, Stéphanie ^a,b,c,d,e   Turpin, Jocelyn ^a,b,c,d,e   Beaumont, Elodie ^f   Roch, Emmanuelle ^f   Berger, Gregory ^a,b,c,d,e,g   Mahieux, Renaud ^a,b,c,d,e   Brand, Denys ^f   Roingeard, Philippe ^f   Cimarelli, Andrea ^a,b,c,d,e  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CNRS   (France)

^e University Lyon i   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

HIV; IFITMs; Interferon; Restriction factors

Indexed keywords

GAG PROTEIN; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 2; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 3; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; DIFFERENTIATION ANTIGEN; IFITM2 PROTEIN, HUMAN; IFITM3 PROTEIN, HUMAN; LEU-13 ANTIGEN; RNA BINDING PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRACELLULAR MEMBRANE; LIFE CYCLE; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROVIRIDAE; TARGET CELL; VIRION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS VIRULENCE; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIRUS ENTRY;

DENGUE VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORTHOMYXOVIRIDAE;

ANTIGENS, DIFFERENTIATION; ANTIVIRAL AGENTS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS; RNA-BINDING PROTEINS; VIRUS ASSEMBLY; VIRUS INTERNALIZATION;

EID: 84934891510     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0103-y     Document Type: Article

References (55)

1. Zhang Z, Liu J, Li M, Yang H, Zhang C: Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS ONE 2012, 7:e49265.
2. Lewin AR, Reid LE, McMahon M, Stark GR, Kerr IM: Molecular analysis of a human interferon-inducible gene family. Eur J Biochem 1991, 199:417-423.
3. Smith SE, Gibson MS, Wash RS, Ferrara F, Wright E, Temperton N, Kellam P, Fife M: Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro. J Virol 2013, 87:12957-12966.
4. Perreira JM, Chin CR, Feeley EM, Brass AL: IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 2013, 425:4937-4955.
5. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, Lall A, Hale C, Rodgers A, Young DB, Haque A, Billker O, Tregoning JS, Dougan G, Kellam P: Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS ONE 2013, 8:e80723.
6. Diamond MS, Farzan M: The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013, 13:46-57.
7. Anafu AA, Bowen CH, Chin CR, Brass AL, Holm GH: Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J Biol Chem 2013, 288:17261-17271.
8. Bailey CC, Huang IC, Kam C, Farzan M: Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 2012, 8:e1002909.
9. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C: The IFITM proteins inhibit HIV-1 infection. J Virol 2011, 85:2126-2137.
10. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M: Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011, 7:e1001258.
11. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009, 139:1243-1254.
12. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi PY, Block TM, Guo JT: Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol 2010, 84:8332-8341.
13. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P: IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012, 484:519-523.
14. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M, Li Q, Zhang Z, Zhang X, Lu S, Doherty PC, Kedzierska K, Xu J: Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A 2014, 111:769-774.
15. Jia R, Pan Q, Ding S, Rong L, Liu SL, Geng Y, Qiao W, Liang C: The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol 2012, 86:13697-13707.
16. Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, Aker AM, John SP, Sarlah D, Carreira EM, Elledge SJ, Kellam P, Brass AL: Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep 2013, 5:895-908.
17. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, Gratton E, Cohen FS, Liu SL: IFITM proteins restrict viral membrane hemifusion. PLoS Pathog 2013, 9:e1003124.
18. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, Elia AE, Everitt AR, Vora M, Pertel T, Elledge SJ, Kellam P, Brass AL: The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol 2013, 87:7837-7852.
19. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA, Smith JM, Packard BZ, Kuhn JH, Costantino J, Garrison AR, Schumaljohn CS, Huang IC, Farzan M, Bavari S: IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol 2013, 87:8451-8464.
20. Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, Liu SL, Guo F, Geng Y, Qiao W, Liang C: Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol 2014, 16:1080-1093.
21. Chesarino NM, McMichael TM, Hach JC, Yount JS: Phosphorylation of the antiviral protein IFITM3 dually regulates its endocytosis and ubiquitination. J Biol Chem 2014, 289:11986-11992.
22. Plemper RK: Cell entry of enveloped viruses. Curr Opin Virol 2011, 1:92-100.
23. Baquero E, Albertini AA, Vachette P, Lepault J, Bressanelli S, Gaudin Y: Intermediate conformations during viral fusion glycoprotein structural transition. Curr Opin Virol 2013, 3:143-150.
24. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB: HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137:433-444.
25. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, Jung JU: The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 2013, 13:452-464.
26. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB: IFITM3 restricts influenza a virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog 2014, 10:e1004048.
27. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC: Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
28. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG: Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 2009, 5:e1000296.
29. Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R, Trono D, Cosset FL: Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100:823-832.
30. Zhu X, He Z, Yuan J, Wen W, Huang X, Hu Y, Lin C, Pan J, Li R, Deng H, Liao S, Zhou R, Wu J, Li J, Li M: IFITM3-containing exosome as a novel mediator for anti-viral response in dengue virus infection. Cell Microbiol 2014. doi:10.1111/cmi.12339.
31. Ott DE: Purification of HIV-1 virions by subtilisin digestion or CD45 immunoaffinity depletion for biochemical studies. Methods Mol Biol 2009, 485:15-25.
32. Grigorov B, Decimo D, Smagulova F, Pechoux C, Mougel M, Muriaux D, Darlix JL: Intracellular HIV-1 Gag localization is impaired by mutations in the nucleocapsid zinc fingers. Retrovirology 2007, 4:54.
33. Woelk CH, Ottones F, Plotkin CR, Du P, Royer CD, Rought SE, Lozach J, Sasik R, Kornbluth RS, Richman DD, Corbeil J: Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res Hum Retroviruses 2004, 20:1210-1222.
34. Nasr N, Maddocks S, Turville SG, Harman AN, Woolger N, Helbig KJ, Wilkinson J, Bye CR, Wright TK, Rambukwelle D, Donaghy H, Beard MR, Cunningham AL: HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood 2012, 120:778-788.
35. Solis M, Wilkinson P, Romieu R, Hernandez E, Wainberg MA, Hiscott J: Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells. Virology 2006, 352:86-99.
36. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, Sandler NG, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miro JM, Palou E, Hoffman M, Massanella M, Blanco J, Woods M, Gunthard HF, de Bakker P, Douek DC, Silvestri G, Martinez-Picado J, Telenti A: Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011, 121:2391-2400.
37. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques DA, Selwood DL, James LC, Noursadeghi M, Towers GJ: HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 2013, 503:402-405.
38. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A: SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007, 4:2.
39. Berger G, Durand S, Goujon C, Nguyen XN, Cordeil S, Darlix JL, Cimarelli A: A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc 2011, 6:806-816.
40. Schlee M, Hornung V, Hartmann G: siRNA and isRNA: two edges of one sword. Mol Ther 2006, 14:463-470.
41. Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, Laustsen A, Hansen K, Ostergaard L, Fitzgerald KA, Xiao TS, Mikkelsen JG, Mogensen TH, Paludan SR: IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci U S A 2013, 110:E4571-E4580.
42. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, Sun L, Chen ZJ: Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 2013, 341:903-906.
43. Cordeil S, Nguyen XN, Berger G, Durand S, Ainouze M, Cimarelli A: Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol 2013, 87:2587-2596.
44. Cavrois M, De Noronha C, Greene WC: A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 2002, 20:1151-1154.
45. Ivankin A, Kuzmenko I, Gidalevitz D: Cholesterol mediates membrane curvature during fusion events. Phys Rev Lett 2012, 108:238103.
46. Ono A, Waheed AA, Freed EO: Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology 2007, 360:27-35.
47. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE: Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001, 17:1009-1019.
48. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, Freiberg AN, Su L, Lee B, Cheng G: Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013, 38:92-105.
49. Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, Guo JT: Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A 2014, 111:6756-6761.
50. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P: Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 2013, 10:146.
51. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West APJ, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, et al: Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 2013, 110:6626-6633.
52. Ding S, Pan Q, Liu SL, Liang C: HIV-1 mutates to evade IFITM1 restriction. Virology 2014, 454-455:11-24.
53. Lambele M, Labrosse B, Roch E, Moreau A, Verrier B, Barin F, Roingeard P, Mammano F, Brand D: Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly. J Virol 2007, 81:125-140.
54. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A: Fiji: an open-source platform for biological-image analysis. Nat Methods 2012, 9:676-682.
55. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, Darlix JL, Cimarelli A: APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 2011, 7:e1002221.